Saxenda month 1 results: what the data says about early GLP-1 weight loss

What did @itsneetab actually say?

She reported losing 10 pounds between June 3rd and July 4th after starting Saxenda (liraglutide), with a total of 12.9 pounds lost since May 11th when she began changing her eating habits. She described minimal side effects, noted injection site reactions that improved after switching to what sounds like a different injection site or technique, and said she's currently on 1.8 mg daily. She also claimed non-scale victories: looser clothes, a slimmer face, and better energy.

She was careful to add: "there's no way to tell how it will do for your body." That caveat matters, and it's worth noting she didn't promise anyone specific results. This is a personal update, not a product endorsement with clinical language, which changes how we should read it.

Does the science back this up?

A 10-pound loss in the first month is on the high end of what clinical trials show, but it's not impossible, especially when dietary changes are happening at the same time. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) found that patients on liraglutide 3.0 mg lost an average of 8.4 kg (about 18.5 lbs) over 56 weeks. Early weight loss in the first four to eight weeks tends to be front-loaded due to water weight, glycogen depletion, and reduced caloric intake from appetite suppression.

She also started modifying her diet in May before adding liraglutide, which means some of that loss is almost certainly from behavioral change alone. That's actually good science in practice: GLP-1 receptor agonists like liraglutide work best as an adjunct to lifestyle changes, not a standalone fix. The drug's mechanism, stimulating insulin secretion, slowing gastric emptying, and reducing appetite centrally, supports exactly the kind of reduced-binge-eating pattern she described.

What did they get right (or wrong)?

She got several things right. The acknowledgment that results vary by individual is accurate and often ignored in these videos. Her framing of the drug as something that's "working for me so far" without guaranteeing it for others is responsible. Her mention of injection site reactions is also consistent with known liraglutide tolerability data; local reactions occur in roughly 14-17% of users per the Saxenda prescribing information.

What's harder to verify is the 1.8 mg dose comment. Standard Saxenda titration starts at 0.6 mg and increases by 0.6 mg weekly, with the target therapeutic dose at 3.0 mg. Being at 1.8 mg at roughly one month is consistent with the approved titration schedule, so that checks out. However, she framed it as waiting to see "how long I can stay on that dose until I need to go up," which slightly mischaracterizes titration. The protocol is to increase to 3.0 mg for full efficacy unless side effects prevent it, not to stay lower indefinitely if tolerated.

What should you actually know?

First-month results on any GLP-1 drug are often the most dramatic and can slow significantly in months two through six. A review by Khera et al. (2016, JAMA) found weight loss with liraglutide plateaus between weeks 40-60, meaning early results aren't predictive of total outcome. If you're watching this and hoping for 10 lbs a month every month, the data does not support that expectation.

Also worth knowing: "non-scale victories" like facial slimming and looser clothes at one month are largely consistent with water and glycogen loss, not necessarily fat loss. That's not bad news, it's just different news. Fat loss becomes more meaningful as the weeks progress. Energy improvements, which she mentions, are plausible given reduced caloric swings from binge eating episodes, though liraglutide itself has limited direct evidence for improving energy levels independent of weight loss.

Saxenda is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It is not a short-term solution, and discontinuation typically results in weight regain, as shown in the SCALE Maintenance trial (Wadden et al., 2013, Obesity).

Bottom line on this video

This is one of the more grounded GLP-1 personal update videos circulating on TikTok right now. She didn't claim the drug cures anything, didn't push a referral code, and explicitly warned viewers their results may differ. The 10-pound figure in 30 days is real-but-context-dependent, and her simultaneous dietary changes make it impossible to isolate liraglutide's contribution. The titration comment contains a small but meaningful misunderstanding about how the dose escalation is supposed to work. Otherwise, this one mostly holds up.